Exavir Therapeutics announces entry into a litigation settlement and license agreement for ultra-long-acting HIV compounds with ViiV Healthcare

ViiV Healthcare will make upfront and milestone payments as well as tiered low-to-mid single digit royalties on future sales of ultra-long-acting HIV compounds